ADC Therapeutics SA (NYSE:ADCT) has been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $48.00.
Several research analysts have issued reports on ADCT shares. HC Wainwright decreased their target price on shares of ADC Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Friday. Zacks Investment Research cut shares of ADC Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 23rd. Finally, Morgan Stanley decreased their price objective on shares of ADC Therapeutics from $55.00 to $53.00 and set an “overweight” rating for the company in a report on Monday, May 10th.
Shares of ADC Therapeutics stock opened at $21.23 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 15.55 and a current ratio of 15.55. The stock has a market capitalization of $1.46 billion and a PE ratio of -9.00. ADC Therapeutics has a 52-week low of $20.21 and a 52-week high of $56.59. The company has a 50-day simple moving average of $24.13 and a two-hundred day simple moving average of $29.57.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE bought a new stake in ADC Therapeutics during the first quarter valued at approximately $44,000. SG Americas Securities LLC bought a new stake in ADC Therapeutics during the first quarter valued at approximately $122,000. Virtus ETF Advisers LLC bought a new stake in ADC Therapeutics during the fourth quarter valued at approximately $276,000. Henry James International Management Inc. bought a new stake in ADC Therapeutics during the first quarter valued at approximately $366,000. Finally, Moneta Group Investment Advisors LLC bought a new stake in ADC Therapeutics during the first quarter valued at approximately $476,000. 40.88% of the stock is owned by hedge funds and other institutional investors.
About ADC Therapeutics
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors.
Read More: What is the Euro STOXX 50 Index?
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.